Associated Papers
Pharmacogenomic Calling From Whole-Exome Sequencing in the Taiwanese Population-A Real-World Experience.
Lin HH et al.
Molecular Genetics & Genomic Medicine, 2026
Germline Variants Influence Chronic Liver Disease Progression through Distinct Pathways.
Vujkovic M et al.
Medrxiv : the Preprint Server for Health Sciences, 2025
Thai pharmacogenomics database -2 (TPGxD-2) sequel to TPGxD-1, analyzing genetic variants in 26 non-VIPGx genes within the Thai population.
John S et al.
Clinical and Translational Science, 2024
Integrated Genomic, Functional, and Prognostic Characterization of Atypical Chronic Myeloid Leukemia.
Fontana D et al.
Hemasphere, 2020
Responder Interferon λ Genotypes Are Associated With Higher Risk of Liver Fibrosis in HIV-Hepatitis C Virus Coinfection.
Moqueet N et al.
The Journal of Infectious Diseases, 2016
Genome-wide significant risk associations for mucinous ovarian carcinoma.
Kelemen LE et al.
Nature Genetics, 2015
Favourable IFNL3 genotypes are associated with spontaneous clearance and are differentially distributed in Aboriginals in Canadian HIV-hepatitis C co-infected individuals.
Moqueet N et al.
International Journal of Molecular Sciences, 2015
Hepatitis C virus and interferon type III (interferon-λ3/interleukin-28B and interferon-λ4): genetic basis of susceptibility to infection and response to antiviral treatment.
Riva E et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases, 2014
Detection of allele specific differences in IFNL3 (IL28B) mRNA expression.
Knapp S et al.
Bmc Medical Genetics, 2014
Genetic predisposition in NAFLD and NASH: impact on severity of liver disease and response to treatment.
Dongiovanni P et al.
Current Pharmaceutical Design, 2013
Natural killer KIR3DS1 is closely associated with HCV viral clearance and sustained virological response in HIV/HCV patients.
Rivero-Juarez A et al.
Plos One, 2013
Genomics and HCV infection: progression of fibrosis and treatment response.
Estrabaud E et al.
Journal of Hepatology, 2012
LDLr genotype modifies the impact of IL28B on HCV viral kinetics after the first weeks of treatment with PEG-IFN/RBV in HIV/HCV patients.
Rivero-Juarez A et al.
Aids (london, England), 2012
Host genomics and HCV treatment response.
Clark PJ et al.
Journal of Gastroenterology and Hepatology, 2012
Analysis of IL28B variants in an Egyptian population defines the 20 kilobases minimal region involved in spontaneous clearance of hepatitis C virus.
Pedergnana V et al.
Plos One, 2012
The impact of human gene polymorphisms on HCV infection and disease outcome.
Schaefer EA et al.
Seminars in Liver Disease, 2011
IL28B single nucleotide polymorphisms in the treatment of hepatitis C.
Lange CM et al.
Journal of Hepatology, 2011
Interleukin 28B Polymorphisms and Hepatitis C-Translating the Association into Clinical Decision Making.
Puri CP
Journal of Clinical and Experimental Hepatology, 2011
Estimating the net contribution of interleukin-28B variation to spontaneous hepatitis C virus clearance.
di Iulio J et al.
Hepatology (baltimore, Md.), 2011
IL28B SNP rs12979860 is a critical predictor for on-treatment and sustained virologic response in patients with hepatitis C virus genotype-1 infection.
Lin CY et al.
Plos One, 2011
IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C.
Urban TJ et al.
Hepatology (baltimore, Md.), 2010
Genome-wide association studies and genetic risk assessment of liver diseases.
Krawczyk M et al.
Nature Reviews. Gastroenterology & Hepatology, 2010
Prediction of response to pegylated interferon plus ribavirin by IL28B gene variation in patients coinfected with HIV and hepatitis C virus.
Pineda JA et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America, 2010
The recent breakthroughs in the understanding of host genomics in hepatitis C.
Rauch A et al.
European Journal of Clinical Investigation, 2010
Pharmacogenomics of chronic hepatitis C therapy with genome-wide association studies.
Wang CH et al.
Journal of Experimental Pharmacology, 2010
Genetic variation in IL28B and spontaneous clearance of hepatitis C virus.
Thomas DL et al.
Nature, 2009
Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance.
Ge D et al.
Nature, 2009